PD-1+ NSCLC Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight

DelveInsight's,“ PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2025 ” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PD-1+ NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in the PD-1 Non-small cell lung cancer market.

Discover the latest drugs and treatment options in the PD-1+ NSCLC Pipeline. Dive into DelveInsight's comprehensive report today! @ PD-1+ NSCLC Pipeline Outlook

Key Takeaways from the PD-1+ NSCLC Pipeline Report

• In May 2025, Elpiscience (Suzhou) Biopharma, Ltd. announced a study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).
• In May 2025, Merck Sharp & Dohme LLC conducted a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%.
• In May 2025, Incyte Corporation organized a study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
• In May 2025, AstraZeneca announced a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
• DelveInsight's PD-1+ NSCLC Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for PD-1+ NSCLC treatment.
• The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.
• Promising PD-1+ NSCLC Pipeline Therapies such as AZD2936, Cisplatin, Carboplatin, PF-06801591, AK112, Chidamide, Envafolimab and others.

Stay ahead with the most recent pipeline outlook for PD-1+ NSCLC. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ PD-1+ NSCLC Treatment Drugs

PD-1+ NSCLC Emerging Drugs Profile

• Zimberelimab: Arcus Biosciences

Zimberelimab is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin's lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin's lymphoma. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. The most advanced study with zimberelimab is in Phase III development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic.

• PM8002: Biotheus

PM8002 is a bispecific antibody candidate with humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations. PM8002 had demonstrated a positive safety profile and encouraging antitumor activity presumably through reduced systemic toxicity by enriching anti-VEGF activity into the tumor microenvironment at ASCO Annual Meeting and ESMO Congress 2023. Currently, the drug is in Phase II/III stage of its clinical trial for the treatment of NSCLC.

• RPH075: R-Pharm

R-Pharm's pembrolizumab biosimilar, known as RPH 075, is a monoclonal antibody classified under antineoplastics, antivirals, and immunotherapies, specifically tumor-agnostic therapies. This biosimilar mimics the action of the originator drug, pembrolizumab, by targeting and antagonizing the programmed cell death 1 (PD-1) receptor on T lymphocytes. By blocking the interaction between PD-1 and its ligands, RPH 075 enhances T-cell mediated immune responses against cancer cells, promoting antibody-dependent cell cytotoxicity and providing a potent means to counteract tumors. Currently, the drug is in Phase I stage of its clinical trial for the treatment of NSCLC.

The PD-1+ NSCLC Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of PD-1+ NSCLC with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1+ NSCLC Treatment.
• PD-1+ NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• PD-1+ NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1+ NSCLC market

Explore groundbreaking therapies and clinical trials in the PD-1+ NSCLC Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New PD-1+ NSCLC Drugs

PD-1+ NSCLC Companies

Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.

PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

PD-1+ NSCLC Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of PD-1+ NSCLC Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ PD-1+ NSCLC Market Drivers and Barriers

Scope of the PD-1+ NSCLC Pipeline Report

• Coverage- Global
• PD-1+ NSCLC Companies- Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.
• PD-1+ NSCLC Pipeline Therapies- AZD2936, Cisplatin, Carboplatin, PF-06801591, AK112, Chidamide, Envafolimab and others.
• PD-1+ NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• PD-1+ NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on PD-1+ NSCLC Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ PD-1+ NSCLC Companies, Key Products and Unmet Needs

Table of Contents